With two earlier trials meeting their primary endpoints, Axsome claimed it has the data to support a filing for FDA approval ...

Axsome Therapeutics said on Monday it would seek marketing approval next year for its oral drug to treat agitation in patients with Alzheimer's disease, after it succeeded in three out of four ...

Shares of Axsome Therapeutics dropped Monday on mixed test results for its Alzheimer's disease agitation treatment.

Axsome Therapeutics said it would submit its Alzheimer’s disease treatment for FDA approval despite mixed results from two ...

Amidst his ongoing fast, 70-year-old farmer leader urges farmer outfits across India to join the agitation for a legal ...

Agitation caused by Alzheimer’s disease currently has one FDA-approved therapy, but that drug brings serious safety risks. An Axsome Therapeutics drug has mixed results from its latest slate of ...

Axsome Therapeutics shows strong revenue growth with promising pipeline drugs for migraine, fibromyalgia, and narcolepsy.

Despite mixed trial results, the ACCORD-2 Phase 3 trial showed significant efficacy in delaying agitation relapse, with AXS-05 demonstrating a notable reduction in severity and risk compared to ...

The doctor would use AXS-05 just long enough to control patients’ agitation, the firm adds. It keeps an Outperform rating on Axsome with a $140 price target Published first on TheFly – the ...

Axsome Therapeutics said on Monday it would seek marketing approval next year for its oral drug to treat agitation in patients with Alzheimer's disease, after it succeeded in three out of four ...